Drug Profile


Alternative Names: FKF02SC; TGOF 02N

Latest Information Update: 08 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Fabre-Kramer Pharmaceuticals
  • Class Antipsychotics
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor modulators; Histamine H1 receptor modulators; Serotonin 1A receptor modulators; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Schizophrenia

Most Recent Events

  • 08 Jan 2016 Phase II development for Schizophrenia is ongoing in USA
  • 08 Jan 2009 FKF 02SC is available for licensing (
  • 08 Jan 2009 Phase-II clinical trials in Schizophrenia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top